Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.ACST · Entity 7266 | Director | August 31, 2023 | September 05, 2023 |
| Retension Pharmaceuticals, Inc.RTSN · Entity 184313 | Director | October 13, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date August 31, 2023 · Filed September 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 381 |
Reported balance
After 2023-08-31 transaction · row 1
1 source rowRow 1 · 2023-08-31 · Purchase · Acquired 381 · Balance 381 |
| Common SharesSEC Table I · non-derivative | IndirectOfra Aslan (Spouse) | 792 |
Reported balance
Holding disclosure · report date 2023-08-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 792 F1: These indirect holdings have been adjusted to give effect to the Company's 1-for-8 reverse stock split, effective August 31, 2021, and the Company's 1-for-6 reverse stock split, effective July 10, 2023. F2: 792 common shares held by Mr. Olds' wife, Ofra Aslan. Mr. Olds disclaims beneficial ownership of the common shares held by his wife and this report shall not be deemed an admission that Mr. Olds is a beneficial owner of such for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These indirect holdings have been adjusted to give effect to the Company's 1-for-8 reverse stock split, effective August 31, 2021, and the Company's 1-for-6 reverse stock split, effective July 10, 2023.
F2: 792 common shares held by Mr. Olds' wife, Ofra Aslan. Mr. Olds disclaims beneficial ownership of the common shares held by his wife and this report shall not be deemed an admission that Mr. Olds is a beneficial owner of such for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Retension Pharmaceuticals, Inc.
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,637 |
Reported balance
After 2026-10-13 transaction · row 1
1 source rowRow 1 · 2026-10-13 · Conversion · Acquired 5,637 · Balance 5,637 F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-13 · Conversion · Disposed 5,637 · Balance 0 F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2026 Filed Oct 13, 2026 22:11 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | ConversionSeries A Convertible Preferred Stock · Derivative | 5,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-109158 · ownership.xml · derivative · entry 2 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. Read SEC document |
| October 13, 2026 Filed Oct 13, 2026 22:11 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | ConversionCommon Stock | 5,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-109158 · ownership.xml · nonDerivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. Read SEC document |
| October 08, 2026 Filed Oct 9, 2026 01:39 UTC | Retension Pharmaceuticals, Inc. RTSN · Entity 184313 | GrantStock Option (right to buy) · Derivative | 5,636 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001213900-26-108189 · ownership.xml · derivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,636 Underlying: Common Stock · 5,636 shares Expires 2036-10-08 F1 · security: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.exercise_date: Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 15:54 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | PurchaseCommon Shares | 381 | $2.05 | $781.05 |
DisclosureSEC source: 0001062993-23-017516 · form4.xml · nonDerivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381 Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 16:36 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014998 · form4.xml · derivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Shares · 12,500 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 16:20 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001171843-22-006334 · ownership.xml · derivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Shares · 45,000 shares Expires 2032-09-28 F1 · derivative.exercise_price: Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 16:21 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 42,100 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008011 · ownership.xml · derivative · entry 1 Olds Donald · CIK 0001807762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,100 Underlying: Class A Common Shares · 42,100 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.